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Surfactant Protein D (SP-D), a pattern recognition innate immune molecule, has been
implicated in the immune surveillance against cancer. A recent report showed an
association of decreased SP-D expression in human prostate adenocarcinoma with
an increased Gleason score and severity. In the present study, the SP-D expression
was evaluated in primary prostate epithelial cells (PrEC) and prostate cancer cell lines.
LNCaP, an androgen dependent prostate cancer cell line, exhibited significantly lower
mRNA and protein levels of SP-D than PrEC and the androgen independent cell lines
(PC3 and DU145). A recombinant fragment of human SP-D, rfhSP-D, showed a dose
and time dependent binding to prostate cancer cells via its carbohydrate recognition
domain. This study, for the first time, provides evidence of significant and specific cell
death of tumor cells in rfhSP-D treated explants as well as primary tumor cells isolated
from tissue biopsies of metatstatic prostate cancer patients. Viability of PrEC was not
altered by rfhSP-D. Treated LNCaP (p53+/+) and PC3 (p53 −/−) cells exhibited reduced
cell viability in a dose and time dependent manner and were arrested in G2/M and G1/G0
phase of the cell cycle, respectively. rfhSP-D treated LNCaP cells showed a significant
upregulation of p53 whereas a significant downregulation of pAkt was observed in both
PC3 and LNCaP cell lines. The rfhSP-D-induced apoptosis signaling cascade involved
upregulation of Bax:Bcl2 ratio, cytochrome c and cleaved products of caspase 7. The
study concludes that rfhSP-D induces apoptosis in prostate tumor explants as well as in
androgen dependent and independent prostate cancer cells via p53 and pAkt pathways.
Keywords: pattern recognition receptor, prostate tumor explants, LNCaP cells, PC3 cells, viability, apoptosis, p53,
pAkt
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INTRODUCTION
Prostate cancer, an adenocarcinoma of epithelial cell-origin, is
the second most frequently diagnosed cancer among men (1).
In its early stages, prostate cancer cells rapidly proliferate in an
androgen dependent manner, and thus, are treated by androgen
deprivation therapy (2). Conventional anti-cancer treatments
such as chemotherapy and radiotherapy improve survival, but
many patients encounter relapse and metastasis. Following the
remittent stage, the cancer progresses to become androgen-
independent where most therapeutic strategies fail.
Immunotherapy by stimulating pattern recognition receptors
of the innate immune system such as toll-like receptors (TLRs)
has shown promise as a preferred adjunct treatment against
cancer (3). Imiquimod, a synthetic imidazoquinoline and an
agonist that targets TLR-7 and induces the production of pro-
inflammatory cytokines including IFN-α, IL-6, and TNF-α,
inhibited cancer growth in the mouse prostate via apoptosis
induction (4, 5).
Collectins are pattern recognition proteins belonging to the
C-type lectin family. They are composed of an N-terminal
cysteine-rich region, a triple-helical collagen domain, an α-
helical coiled-coil neck region, and C-terminal carbohydrate
recognition domain (CRD) (6). Surfactant Protein D (SP-D)
is one of the most studied collectins with a vital role in
host defense against pathogens and allergens, and modulation
of inflammatory response (6). Although SP-D was historically
shown to be lung-resident being produced by type II alveolar and
Clara cells (7), studies during the last decade have established its
extrapulmonary existence in a range of tissues (8). SP-D has also
been shown to be expressed in the male reproductive tracts of
human and mice (9, 10). Elevated levels of SP-D at inflamed sites
in the prostate manifested protection against bacterial infection
(11, 12). Kankavi et al. (13) observed differential expression
of SP-D in glandular structures of inflamed malignant and
non-malignant human prostate tissues. There was a significant
correlation between decreased levels of SP-D and increased
Gleason score, a grading system based on the histologic pattern
of arrangement of carcinoma cells, and tumor volume.
Previously, we reported a novel anti-cancer role of human
SP-D and its recombinant fragment (rfhSP-D) comprising 8
Gly-X-Y repeats neck and CRD region, wherein they reduced
the viability of a range of human cancer cell lines including
eosinophilic leukemia cell line (AML14.3D10) (14). Importantly,
survival of peripheral blood mononuclear cells (PBMCs) derived
from healthy individuals was found to be unaltered (14). rfhSP-
D treated AML14.3D10 cells showed a significant increase in
apoptosis with reduced HMGA1 levels and increased levels of
activated p53 and caspase 9 (14). SP-D has recently been shown
to inhibit the proliferation, migration and invasion of A549
human lung adenocarcinoma cells by binding to N-glycans of
epidermal growth factor receptor (EGFR) via its CRD region,
and interfering with EGF signaling (15). In UV treated apoptotic
Jurkat T cells, SP-D enhanced membrane and nuclear blebbing,
suggesting involvement of SP-D in induction of apoptosis (16).
Exogenous treatment of SKOV3 cells (an ovarian cancer cell line)
with rfhSP-D led to increased caspase 3 cleavage and induction of
pro-apoptotic genes Fas and TNF-α (17).
To take the next logical step from the reported anti-
cancer role of SP-D in tumorigenic cell lines, we examined
anti-prostate cancer role of rfhSP-D using tumor explants
and primary cells derived from tissue biopsies of metastatic
prostate cancer patients. rfhSP-D induced apoptosis selectively
in various prostate cancer cells including the two prostate
cancer cell lines (LNCaP and PC3) in a dose- and time-
dependent manner. Apoptotic signaling involved upregulation
of p53 and downregulation of pAkt. Decreased levels of
Bcl2, with a concomitant increase in Bax, cytochrome c and




The study was approved by the Institutional Ethics Committee
for Clinical Studies, ICMR- National Institute for Research in
Reproductive Health; (Project No.: 260/2014) and Institutional
Ethics Committee, Tata Memorial Hospital (Study no: 1467).
Tissue biopsy samples were collected from 9 suspected
metastatic prostate cancer patients (treatment naïve) undergoing
Transrectal Ultrasound guided multiple core needle biopsy,
with written informed consent. Chemotherapy was initiated in
the patients after confirmation of metastasized prostate cancer.
Information regarding the androgen dependency of the prostate
cancer in these patients was not available. Average age of
the study participants was 67.4 ± 3.97 years with Mean PSA
(Prostate- specific antigen) level of 190.04 ± 85.12 ng/ml and
Median Gleason score of 8± 0.83.
Explant and Cell Culture
Prostate tissue biopsies were collected in cold Phosphate Buffer
saline containing 10% v/v fetal bovine serum (FBS; GIBCO) and
2% v/v Pen-Strep solution (GIBCO) and immediately processed
in sterile conditions. Biopsies were cut into 5mm explants, placed
in the scratched areas of 35mm tissue culture plate (Nunc) and
cultured in RPMI 1640 (GIBCO) supplemented with 10% FBS,
1% Pen-Strep solution, Glucose (1 mg/ml) (HiMedia) and 1%
Sodium Pyruvate (GIBCO) (complete RPMI) for a week. Primary
Cancer Epithelial Cells (PrCEC) isolated from the explants
were sub-cultured using 5mM EDTA (Sigma) in PBS and
passaged further. Isolated PrCEC (Passage 2) were examined for
Cytokeratin (an epithelial cell marker) via immunofluorescence
microscopy (Anti-cytokeratin antibody, Dako, 1:500) and by
Real time RT-PCR analysis for CD164 expression, a marker for
metastatic epithelial cell cancer (18). Isolated PrCECwere stained
for the presence of Alpha-methylacyl-CoA racemase (AMACR)
expression, which is upregulated in prostate cancer with high-
grade prostatic intraepithelial neoplasia (HGPIN) than in the
normal human prostate (19). PrEC, PrCEC and PC3 cells were
stained using mouse monoclonal antibodies to AMACR (Novus
Biologicals, 1:100) or matched-isotype control IgG for 1 h at
4◦C. Phycoerythrin-conjugated rat anti-mouse IgG (Molecular
Probes, Eugene, USA) was used as secondary antibody. The gated
cell population was determined using PE tagged anti-AMACR.
Cells were analyzed via BD FACS Aria III (BD Biosciences, San
Jose, California, USA) flow cytometer.
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Human prostate cancer cell lines, LNCaP (androgen
dependent, p53+/+), DU145 (androgen independent p53+/−)
and PC3 (androgen independent, p53−/−) (ATCC, Rockville,
MD, USA) were cultured in complete RPMI 1640 medium.
Human primary prostate epithelial cells (PrEC; LONZA)
were maintained in Prostate epithelial growth medium
(PrEGM Bulletkit) supplemented with Triiodothyronine
(T3), Transferrin, Bovine Pituitary Extract (BPE), recombinant
human Epidermal growth factor (rhEGF), GA-1000, Insulin,
Hydrocortisone, Epinephrine, and retinoic acid (LONZA,
Cat no. CC-3165). All experiments with Human PrEC were
completed within first five passages. Cells were grown at 37◦C
under 5% v/v CO2 until 70–80% confluency was attained.
rfhSP-D Preparation
The recombinant fragment of human SP-D (rfhSP-D) was
expressed in Escherichia coli BL21 (λDE3) pLysS (Invitrogen),
purified and characterized, as described previously (15).
Endotoxin level in the rfhSP-D preparation was determined using
the QCL-1000 Limulus amebocyte lysate system (BioWhittaker
Inc., USA). The assay was linear over a range of 0.1–1.0
EU/ml (10 EU = 1 ng of endotoxin) and the amount of
endotoxin present in the preparations was found to be <4 pg/µg
of rfhSP-D.
Interaction Between FITC Labeled rfhSP-D
and Prostate Cells
rfhSP-D was labeled with FITC dye (20) and incubated with
prostate epithelial cells and prostate cancer cells at 5, 10, and
20µg/ml concentration in staining buffer for 15, 30, 45, and
60min at 4◦C in the presence of 2mM CaCl2. Cells were washed
to remove unbound rfhSP-D and fixed with 2% PFA for analysis
via BD FACSAria III (BD Biosciences, San Jose, California, USA).
Data was analyzed using FCS Express 6 De Nova software. To
assess the specificity of the interaction, PC3 cells were incubated
with FITC labeled rfhSP-D in the presence of 5mM CaCl2, or
5mM EDTA, or 5mM Glucose in PBS, pH 7.4. Staining buffer
was used as control for these experiments.
Cell Viability Assay
Human PrEC (passage no. 3–5), LNCaP, PC3, or PrCEC (passage
no. 3–5) cells (5× 103) were placed in 96-well tissue culture plates
(Nunc) and grown overnight. Cells were then starved in cell
appropriate serum free media (PrEC and PrCEC for 4 h; LNCaP
cells for 12 h; PC3 cells for 18 h) and treated with rfhSP-D (5,
10, and 20µg/ml) for 24, 48, and 72 h. Cells alone in the culture
medium served as an untreated control. After incubation 10
µl MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide] (5 mg/ml stock) was added to each well and incubated
at 37◦C for 4 h. Formazan crystals were dissolved in acidified iso-
propanol and absorbance was read at 570 nm (Beckman Coulter).
Cell Cycle Analysis
LNCaP or PC3 cells (2× 104) were plated in 12-well tissue culture
plate, starved for 18 h in serum-free RPMI medium serum-free
RPMI medium, and then treated with rfhSP-D (20µg/ml) for
48 h. After incubation, cells were trypsinized, suspended in cold
hypotonic solution containing 0.1% sodium citrate, 0.3 µl/mL
of NP-40 (Sigma), 2 mg/mL RNaseA (Thermo Fisher Scientific),
and 50µg/mL Propidium Iodide (PI; Sigma) for 20min, and
then analyzed using BD FACS Aria III using BD FACS DIVA
software (21).
Fluorescence Microscopy for Nuclear
Morphology
PrEC, LNCaP, or PC3 cells (2 × 103) were grown on coverslips
and incubated with rfhSP-D (20µg/ml) for 48 h to analyze
nuclear morphology following induction of apoptosis. Cells
were fixed in 2% PFA and permeabilized using 1% v/v Triton
X 100 (Sigma). Cells were incubated with Hoechst (1:10,000,
Invitrogen) for 20min in dark. Coverslips were mounted in
vector shield (Vector laboratories, UK) and observed under
confocal microscope (Zeiss, Germany).
TUNEL (Terminal Deoxynucleotidyl
Transferase dUTP Nick end Labeling)
Assay
Prostate tissue biopsies collected from metastatic prostate cancer
patients were incubated with rfhSP-D (40µg/ml) for 48 h in
serum free RPMI medium at 37◦C under 5% v/v CO2. Five
micrometer paraffin embedded sections of 10% NBF (neutral-
buffered formalin) fixed prostate tissue biopsies were placed
on poly L-lysine coated slides. The sections were fixed with
chilled acetone followed by washing with PBS. Slides were
incubated in TUNEL Mix (Roche Diagnostics), containing
terminal deoxynucleotidyl transferase (TdT) and fluorescein
labeled nucleotides for an hour in a moist chamber at 37◦C.
The slides were washed and counterstained with DAPI (4′,6-
diamidino-2-phenylindole). TUNEL positive apoptotic cells
(green-stained cells) were viewed under confocal microscope
(Zeiss, Germany).
Annexin V Assay
For Annexin-V immunostaining, the manufacturer’s protocol
of Annexin V-FITC apoptosis detection kit (Calbiochem) was
followed with some modifications. PrEC, LNCaP, or PC3 were
treated with indicated concentrations of rfhSP-D and harvested
at the end of 24 and 48 h. Cells were trypsinized and washed
with ice cold PBS to remove culture supernatant, followed by
incubation with FITC-tagged Annexin V for 20min in dark.
Subsequently, Annexin V was washed and 1 µl PI was added to
stain the DNA. Cells were immediately analyzed via BD FACS
Aria III.
Western Blot
PC3 or LNCaP cells (1 × 106) were plated in a six-well plate
and incubated with or without rfhSP-D (20µg/ml), in serum-free
RPMI medium for 12 h and 24 h. The cells were lysed in lysis
buffer (50mM Tris-HCL, pH7.5, 150mM NaCl, 1% Triton X,
1mMSodium orthovanadate, 10mM β- glycerophosphate, 2mM
EDTA, 10mM Sodium pyrophosphate) and analyzed by western
blotting. Lysate proteins (30 µg) were separated on 15% SDS-
PAGE polyacrylamide gel and electrophoretically transferred
onto PVDF membranes (Pall Corporation, NY, USA). The blot
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was probed with primary antibodies raised against human SP-
D [a gift from Uffe Holmskov, (13)], Phosphorylated-p53 (Ser
15) (Cell Signaling Technology), pAKT (PathScan R© Multiplex
Western Cocktail I), pan Akt (ABclonal), phospho-Bad-S155
(ABclonal), Bcl-2 associated death promoter (Bad) (Apoptosis
I sampler Kit), Bcl-2-associated X protein (Bax) (Apoptosis I
sampler Kit), B-cell lymphoma 2 (Bcl2) (Apoptosis I sampler
Kit) or caspase 7 (Cell Signaling Technology), followed by HRP-
conjugated secondary antibodies. All western blot images were
acquired by Syngene (Chem Genius) and quantified by Syngene
Gene Tools.
Enzyme-Linked Immnosorbent Assay
(ELISA) for SP-D and Cytochrome c
Cell lysates and culture supernatants were analyzed for SP-
D levels (Duo Set Human SP-D, catlog no. DY1920, R & D
Systems) and Cytochrome c (Human Cyt-C, catlog no. E1516Hu,
BT Assay) using commercially available ELISA kits. Briefly, for
quantification of cytochrome c, PrEC, LNCaP, PC3 cells, or
Prostate tissue biopsies collected from metastatic prostate cancer
patients were incubated with indicated concentrations of rfhSP-
D for 48 h. Cell culture supernatant was analyzed for cytochrome
c released by cells. Color development was stopped using 2N
H2SO4 and optical density was determined at 450 nm using a
microplate reader (Beckman Coulter).
Real Time PCR
PrEC, PrCEC, PC3, and LNCaP cells (1 × 106) were plated in a
six-well plate and total RNA was isolated using Trizol (Takara)
that was further treated with DNase I (Thermo Scientific,
Rockford, USA) at 37◦C for 30min to eliminate genomic DNA
contamination. One to two microgram of total RNA was reverse
transcribed into cDNA using Superscript III first strand synthesis
kit (Invitrogen, USA). One microliter of cDNA was used for real
time PCR reactions using BioRad CFX96 TouchTM real-time
PCR detection system and iQTM SYBR Green Supermix (Bio-
Rad, Hercules, CA, USA). 18S was used as housekeeping control.
Each qPCR experiment was performed in triplicates and each
experiment was repeated 3 times. Primers were designed using
NCBI Primer BLAST Software and their annealing temperatures
and product sizes are mentioned in Table 1.
In silico Analysis of Human SP-D Promoter
Region for Androgen Responsive Elements
In silico analysis was carried out to predict putative androgen
responsive elements (ARE) in promoter regions of human SP-
D gene using MatInspector Genomatix v3.4 Software, GmbH,
Munchen (Germany). The transcription start site (TSS) for SP-
D was determined from the Institute of Bioinformatics and
Applied Biotechnology (IBAB) MGEx-Tdb database. Promoter
regions −10,000 bp upstream and +1,000 bp downstream
from the transcription start site (TSS sites) were submitted
for analysis.
Statistical Analysis
GraphPad PRISM Software version 6.00 (GraphPad Software
Inc., San Diego, CA) was used to plot the graphs and
analyze the data using one-way ANOVA with Bonferroni
corrections for comparison among prostate cells or
unpaired two tailed Student’s t-test for comparing the
rfhSP-D treated groups with control. Data is represented
as mean ± SD. Values of p < 0.05 were considered
statistically significant.
RESULTS
Prostate Epithelial and Cancer Cells
Expressed SP-D
Since it is known that prostate epithelial cells secrete SP-D
(11, 13), we evaluated SP-D expression and its regulation in
PrEC, LNCaP, DU145, and PC3. Figure 1A shows that SP-D is
expressed by prostate epithelial cells and prostate tumor cells; SP-
D expression in LNCaP cells is significantly lower in comparison
with DU145 (p < 0.05), PC3 (p < 0.05), and PrEC (p <
0.05) by western blot and ELISA (PrEC-1.48 ± 0.31 pg of SP-
D/µg of total protein; LNCaP-1.26 ± 0.28 pg/µg; DU145-1.50
± 0.35 pg/µg, data not shown). SP-D was detectable in the cell
culture supernatants of various prostate cells (Range-150 ± 21
to 260 ± 35 pg/ml), suggesting that SP-D is secreted, though
not sufficient enough to induce apoptosis (10–20µg/ml) (14).
It is reported that androgen induces proliferation of prostate
epithelial cells and LNCaP cells via androgen receptors (22).
Furthermore, SP-D expression in rodent prostate is altered on
castration (11). Hence, we evaluated levels of SP-D transcripts
in Dihydrotestosterone (DHT) treated PrEC, LNCaP, and PC3
cells. Treatment with DHT (10 nM) significantly upregulated
SP-D transcripts in both PrEC and LNCaP cells by 1.9 fold
but not in PC3 cells (androgen independent) (Figure 1B). This
suggests that SP-D expression is regulated by androgens (DHT)
in androgen dependent cancer. Increased cell viability was
observed in DHT treated PrEC (111.43 ± 4.69%) and LNCaP
(119.23 ± 2.68%) cells as reported [Figure 1B (ii)]. In silico
analysis of promoter region of human SP-D gene elucidated
10 putative Androgen Responsive Elements (AREs) (Table 2),
suggesting that androgens may regulate SP-D expression. The
functionality of identified ARE has not been evaluated in
this study.
rfhSP-D Binds Differentially to Prostate
Cancer Cells
FITC-labeled rfhSP-D showed a dose and time dependent
binding to PrEC and prostate cancer cells (LNCaP, DU145,
and PC3) (Figure 2). A significantly higher binding was
observed with the androgen independent PC3 cells (MFI-743.86
± 67.41) than the androgen dependent LNCaP cells (MFI-
354.75 ± 54.11) (p < 0.05) (Figure 2A). PrEC (MFI-96.48
± 21.07) showed comparatively less binding with the FITC-
labeled rfhSP-D than any of the cancer cells (PC3, LNCaP,
p < 0.05). Binding of rfhSP-D to all cell types was calcium-
and carbohydrate-dependent that was inhibitable by EDTA and
glucose (Figures 2B,C show representative binding to PC3 cells).
DU145 cells showed results similar to that of PC3 cells (data
not shown).
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TABLE 1 | Primer sequences.
Transcripts Forward primer (5′-3′) Reverse primer (5′-3′) Tm (◦C) Product size (in bp)
SP-D AGGCTGCTTTCCTGAGCATGAC CCATTGGTGAAGATCTCCACACAG 57.8 148
CD164 GACTTTAGCGCCCATCTCCA GCCGTGGAAACGGAACAGAA 68 233
BCL2 GCGTCAACCGGGAGATGTCGCCC TTTCTTAAACAGCCTGCAGCTTTG 66 208
BAX AGTGACCCCTGACCTCACTG GCAGGGGACTGAGATGAACG 68 296
BAD GAGCTCCGGAGGATGAGTGA CAAGTTCCGATCCCACCAGG 68 141
18S GGAGAGGGAGCCTGAGAAAC CCTCCAATGGATCCTCGTTA 64 174
FIGURE 1 | SP-D expression is regulated by Dihydrotestosterone (DHT) in prostate cells. (A) Levels of SP-D protein by immunoblotting (i) and transcripts by real time
RT-PCR (iii) in PrEC, DU145, PC3, and LNCaP cell lysates. Panel (ii) shows densitometric analysis for the SP-D expression in PrEC, DU145, PC3, and LNCaP cells; n
= 3 independent experiments, error bar represents the S.D. *p < 0.05. (B) (i) SP-D transcripts in PrEC, LNCaP, and PC3 cells treated with DHT (10 nM) for 48 h. *p <
0.05 relative to untreated controls; n = 3 independent experiments, error bar represents the S.D. (ii) Cell viability of PrEC, LNCaP, and PC3 cells incubated with DHT
(10 nM) for 48 h by MTT assay. Each bar represents % viability ± S.D of three independent experiments. *p < 0.05, relative to untreated controls.
TABLE 2 | Putative Androgen Responsive Elements in the promoter region of human SP-D genea.
Sr. Start End Anchor Core Sim. Matrix Sim. Strand Sequence
1 ARE 904 922 913 0.898 0.938 + ataagacctcctGTGCtcc
2 ARE 2,339 2,357 2,348 1 0.895 – gaaatgcttaaaGTTCtaa
3 ARE 3,787 3,805 3,796 1 0.912 – ccaaagctttgtGTTCcct
4 ARE 5,430 5,448 5,439 0.878 0.901 + ttttttctttcaGTACttt
5 ARE 5,851 5,869 5,860 1 0.912 + ttttttctttttGTTCctc
6 ARE 7,481 7,499 7,490 1 0.941 + gccataccttatGTTCtgc
7 ARE 7,589 7,607 7,598 1 0.8 + caggtgctatcTGTTgttg
8 ARE 8,303 8,321 8,312 0.875 0.945 – gctgcacccactGTCCtgc
9 ARE 8,366 8,384 8,375 0.869 0.896 – ccctgaccccttGTGCtct
10 ARE 9,883 9,901 9,892 0.959 0.907 – ttctctctggctGTCCtta
aMatInspector Genomatix v3.4 Software was used for in silico analysis of human SP-D gene promoter region −10,000 bp upstream to +1,000 bp downstream from the TSS site.
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FIGURE 2 | rfhSP-D differentially binds to normal prostate epithelial cells and cancer cells. (A) Binding of FITC labeled rfhSP-D to normal prostate epithelial cells
(PrEC) and cancer cell lines (LNCaP and PC3) (representative histograms). Black dotted line represents unstained cells, black line shows rfhSP-D (20µg/ml) binding to
(i) PrEC, (ii) LNCaP, (iii) PC3 in comparison to their respective unstained. Each experiment was repeated three times. (B) Mean Fluorescence Intensity (MFI) of FITC
labeled rfhSP-D binding to PC3 cells (i) at different doses of rfhSP-D and, (ii) time intervals. Data represents mean ± S.D of three independent experiments. *p < 0.05,
vs. unstained cells. (C) Involvement of CRD region of rfhSP-D in its interaction with PC3 cells. (i) PC3 cells were incubated with FITC labeled rfhSP-D alone and in the
presence of 5mM Calcium (Ca2+) or 5mM Ca2+ and 5mM EDTA (EDTA) or 5mM Ca2+ and 5mM Glucose (Glc). A representative FACS histogram of PC3 cells with
FITC-labeled rfhSP-D (20µg/ml) showing decreased binding in presence of EDTA and glucose. (ii) Data are Mean ± S.D. of the mean fluorescence intensity of
rfhSP-D binding to the PC3 cells relative to control; n = 3 independent experiments. *p < 0.05.
Anti-prostate Cancer Activity of rfhSP-D in
PrCEC and Tumor Explants
We first carried out a pilot investigation on the effect of rfhSP-
D on the primary cells derived from tissue biopsies of metastatic
PCa patients (n= 9). Isolated PrCEC (Passage 2) showed positive
staining for Cytokeratin (Figure 3C). Expression of AMACR
(which is upregulated in prostate cancer with high-grade
prostatic intraepithelial neoplasia) in PrCECwas not significantly
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FIGURE 3 | rfhSP-D reduced viability of primary Cancer Epithelial Cells (PrCEC) isolated from the metastatic prostate cancer tissue biopsies and enhanced apoptosis
in tumor explants. (A) FACS analysis of PE tagged anti-AMACR (prostate cancer marker) expression in PrEC (n = 3) (i), PC3 (n = 3) (ii), and isolated PrCEC (n = 9) (iii)
cell population (representative histograms). Dotted black line histogram represents isotype control. The black line histogram indicates AMACR expression. Data (iv)
represents mean of positively stained AMACR cell population (%), error bar represents the S.D. *p < 0.05 vs. PC3. (B) Transcript levels of CD164 (marker for
metastatic epithelial cell cancer) in PrEC (n = 3), PC3 (n = 3), and PrCEC (n = 9). Data represents the mean of three independent experiments, error bar represents
the S.D. *p < 0.05 vs. PrEC. (C) Positive immunofluorescence staining for FITC tagged anti-Cytokeratin, a marker for epithelial cells. Inset: Higher magnification, Scale
bar = 20µm. (D) PrCEC were incubated with different concentrations of rfhSP-D (5, 10, or 20µg/ml) for the indicated time intervals (24, 48, and 72 h) (n = 5). Each
bar represents % viability ± S.D, *p < 0.05, relative to untreated controls. (E) TUNEL assay of tissue biopsies from metastatic prostate cancer patients exogenously
treated with rfhSP-D (40µg/ml) for 48 h. Untreated tissue biopsy (i) showed significantly less number of TUNEL positive cells when compared with the treated biopsy,
(ii) from the same individual. Scale bar, 20µm. (iii) TUNEL+ve cells were quantitated and are shown as the number of TUNEL+ve cells per section (six sections per
tissue biopsy). *p < 0.05, relative to untreated controls.
different than the PC3 cells whereas PrEC cells showed
significantly decreased expression (Figure 3A). PrCEC and PC3
cells showed significantly upregulated expression of CD164 in
comparison with PrEC (Figure 3B). PrCEC cells isolated from
themetastatic PCa patients showed significantly reduced viability
in a dose- and time-dependent manner following treatment
with rfhSP-D (Figure 3D). Importantly, TUNEL assay confirmed
increased apoptosis in rfhSP-D treated tissue biopsies of the same
patients (Figure 3E). Since these metastatic PCa patients were
not evaluated for androgen-dependency, we could not assess if
rfhSP-D induced cancer cell death would vary with androgen
resistance. Therefore, we pursued further studies to delineate
the molecular mechanisms for rfhSP-D mediated apoptosis in
androgen dependent (LNCaP) and independent (PC3) cancer
cell lines.
rfhSP-D Selectively Reduced the Viability
of Prostate Cancer Cells
Reduction in the viability of PCa cells following
rfhSP-D treatment was dose- and time-dependent,
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FIGURE 4 | rfhSP-D treated LNCaP and PC3 cells showed increased cell cycle arrest. (A) (i) Normal prostate epithelial cells (PrEC); prostate cancer cell lines, LNCaP
(ii) and PC3 (iii) were incubated with different concentrations of rfhSP-D (5, 10, or 20µg/ml) for the indicated time intervals (24, 48, and 72 h). Each bar represents %
viability ± S.D. of three independent experiments. *p < 0.05, relative to untreated controls. (B) (i) LNCaP (p53+/+) cells and (ii) PC3 (p53−/−) cells were incubated in
the presence of rfhSP-D (20µg/ml) or in culture medium alone (control) for 48 h and were subjected to flowcytometric cell cycle analysis. The figure is a representative
histogram of one of the three independent experiments. The total population of cells has been divided in the G1, S, and G2 phases and analyzed using BD FACS DIVA
software. Treated LNCaP (p53+/+) cells showed growth arrest in G2/M phase (14.8 ± 1.7%) in comparison with the untreated cells (8.36 ± 1.58%) (p < 0.05).
Treated PC3 (p53−/−) cells showed growth arrest in G0/G1 phase (79.3 ± 3.02%) in comparison with the untreated cells (69.6 ± 4.50%) (p < 0.05).
TABLE 3 | IC50 values of rfhSP-D induced cell death in various prostate cancer
cells at 48 h.
Prostate cancer cells IC50 for rfhSP-D (µg/ml)
PrEC 94.54 ± 3.97
LNCaP 23.14 ± 3.70
PC3 31.98 ± 3.42
DU145 24.80 ± 2.94
irrespective of their androgen sensitivity whereas the
viability of rfhSP-D treated PrEC was unaltered till 48 h
(Figure 4A). The half-maximal inhibitory concentration
(IC50) of rfhSP-D against the PCa cells is tabulated
as Table 3.
rfhSP-D Caused Blockade in the Cell Cycle
of Prostate Cancer Cells
We further analyzed the effect of rfhSP-D on the percentage
of cells in various phases of the cell cycle (Figure 4B). rfhSP-
D treatment significantly reduced the S-phase peak with an
accumulation of cancer cells in either G0/G1 or G2/M cell cycle
phases. At 48 h, we observed growth arrest of LNCaP (p53+/+)
cells in G2/M (14.8± 1.7%) as compared to the untreated control
(8.36 ± 1.58%) (p < 0.05). There was a significant increase
(79.3 ± 3.02%) in G0/G1 population in the rfhSP-D treated PC3
(p53−/−) cells, in comparison with the untreated cells (69.6 ±
4.50%) (p < 0.05). Cell cycle inhibition following treatment with
rfhSP-D was consistent with the cell viability results. No cell
cycle arrest was observed in the PrEC (data not shown), which
confirmed that the rfhSP-Dmediated cell cycle arrest was specific
to cancer cells.
rfhSP-D Induced Apoptosis in LNCaP and
PC3 Cells
Annexin-V, a classical marker of the apoptosis, was evaluated by
flow cytometry. A significant increase in the annexin-V positive
cells was observed post 48 h in rfhSP-D treated LNCaP (19.13 ±
2.69%[Q2] and 25.82± 1.14% [Q4]) (p< 0.05) and PC3 (40.32±
2.24% [Q2] and 7.405± 1.63% [Q4]) (p< 0.05) cells as compared
to treated PrEC (2.63 ± 1.41% [Q2] and 3.9 ± 1.95% [Q4])
(Figure 5A). rfhSP-D promoted karyorrhexis (fragmentation of
nucleus) of LNCaP and PC3 cells at 48 h, as seen in Hoechst
stained cells (Figure 5B).
rfhSP-D Triggered Intrinsic Mitochondrial
Apoptosis in the Prostate Cancer Cells
p53 and PI3K/Akt are involved in several cellular physiological
processes including apoptosis and cell proliferation. Our
previous study had shown involvement of p53 in the rfhSP-D
mediated apoptosis of AML14.3D10 cells (12). Here, rfhSP-D
treated LNCaP cells with a wild type p53, showed significant
upregulation of p53 (Figure 6A). To understand the other likely
mechanisms of apoptosis, p53 null PC3 cells were examined
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FIGURE 5 | Significant increase in apoptosis in rfhSP-D treated prostate cancer cells. (A) Dot blots showing Annexin V-FITC and PI staining of PrEC, LNCaP, and PC3
cells incubated with rfhSP-D (20µg/ml) for 24 and 48 h. Q1 represents necrotic cells, Q2 show Annexin V FITC and PI double positive cells in late apoptosis, Q3 is
unstained cells and Q4 represents Annexin V FITC positive cells in early apoptosis. (i) LNCaP 24 h control, (ii) LNCaP 24 h rfhSP-D treated, (iii) LNCaP 48 h control, (iv)
LNCaP 48 h rfhSP-D treated, (v) PC3 24 h control, (vi) PC3 24 h rfhSP-D treated, (vii) PC3 48 h control, (viii) PC3 48 h rfhSP-D treated, (ix) PrEC 48 h control, (x) PrEC
48h rfhSP-D treated. The figure shows representative histograms from one of the three independent experiments. The total cell population has been divided into four
quadrants and analyzed using FCS Express 6 software. (B) Fluorescence microscopy images showed that rfhSP-D promotes karyorrhexis of LNCaP and PC3 cells at
48 h after staining with highly diluted Hoechst DNA stain (1µg/ml). (i), (iii), and (v) represent normal nuclear morphology of PrEC, LNCaP, and PC3 cells; (ii), (iv), and (vi)
represent effect of rfhSP-D on nuclear morphology of PrEC, LNCaP, and PC3 cells. “White arrows” indicate disintegrated nucleus. Scale bar, 20µm. (vii) Percent
apoptotic cells was recorded in all the cell types with and without rfhSP-D treatment, each bar represents the mean ± S.D. of three independent experiments. *p <
0.05 relative to untreated controls.
(Figure 6B) for differential expression of several kinases (MAPK,
JAK, Stat-1, ERK, and Akt). rfhSP-D significantly decreased the
phospho-active forms of Akt in PC3 cells at 15min (Figure 6B
iii and iv). Interestingly, treated LNCaP cells also showed
significantly decreased pAkt at 30min (Figure 6B i and ii).
Phosphorylated Akt leads to increased phosphorylation of Bad,
an inactive form of Bad. The rfhSP-D induced decrease in pAkt
sequentially led to a significant decrease in phosphorylated Bad
in both the cell lines (Figure 7A). rfhSP-D treatment further led
to a significantly decreased level of Bcl2 and an increased level
of Bax at 24 h (Figure 7B). Both LNCaP and PC3 cells showed
a significant increase in Bax to Bcl-2 ratio (p < 0.05) upon
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FIGURE 6 | Levels of p53 and pAkt were altered in rfhSP-D treated prostate cancer cells. (A) LNCaP cells (i) incubated with rfhSP-D (20µg/ml) for 12 and 24 h were
analyzed for the levels of anti-phosphorylated-p53(Ser 15) (Cell Signaling Technology) by immunoblotting. Densitometric analysis for the same is shown in panel, (ii) n
= 3 independent experiments. *p < 0.05 vs. control. (B) LNCaP (i) and PC3 (iii) cells treated with rfhSP-D (20µg/ml) for 5, 15, and 30min were analyzed for anti-pAkt
(PathScan Multiplex Western Cocktail I) and anti-pan Akt (ABclonal) expression by western blot. Their respective densitometric analysis is shown as pAkt/Akt ratio in
(ii) and (iv). n = 3 independent experiments. *p < 0.05, **p < 0.01 vs. control. Full length western blots provided as Supplementary Information.
treatment with rfhSP-D. Similarly, transcripts for pro-apoptotic
genes like BAX, BAD were upregulated and transcripts of BCL2
an anti-apoptotic gene was down regulated in a time dependent
manner in LNCaP and PC3 cells (Figure 8). In LNCaP cells,
transcripts for BAX (by 1.5 folds) were upregulated during 12 h of
rfhSP-D incubation; in PC3 cells, transcripts for BAD (by 6 folds)
were significantly upregulated at 6 h of rfhSP-D incubation.
To delineate the penultimate steps of apoptotic cascade,
we assessed levels of cytochrome c and activation of caspases
in rfhSP-D treated prostate cancer cells. At 48 h, rfhSP-D
treatment induced release of cytochrome c attained significance
in culture supernatant of cancer cells (LNCaP, PC3) and
tissue biopsies of prostate cancer when compared to PrEC
(Figure 7D). Cleaved products of the executioner caspase 7 were
significantly increased after 24 h following rfhSP-D treatment
(Figure 7C). From these observations, we infer that rfhSP-D
triggers intrinsic mitochondrial pathway of apoptosis in prostate
cancer cells.
DISCUSSION
The present study established the anti-prostate cancer activity
of rfhSP-D via induction of intrinsic apoptosis in explants and
primary tumor cells isolated from tissue biopsies of metastatic
prostate cancer patients and prostate cancer cell lines: LNCaP
(androgen responsive) and PC3 (androgen resistant). Various
attributes of apoptosis like phosphatidylserine externalization
(Figure 5), mitochondrial dysfunction (Figure 7), and DNA
fragmentation (Figure 5) and various apoptotic markers
(Figure 7) were observed in the rfhSP-D treated LNCaP and PC3
cells. Viability of the normal prostate epithelial cells (PrEC) was
not altered in presence of rfhSP-D (Figure 1).
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FIGURE 7 | rfhSP-D triggers intrinsic apoptotic pathway. (A) LNCaP (i) and PC3 (iii) cells treated with rfhSP-D (20µg/ml) for 12 and 24 h were analyzed for anti-pBad
(Ser 155) (ABclonal) and anti-Bad (Apoptosis I sampler Kit, Cell Signaling Technology) expression by immunoblotting. Panels (ii) and (iv) show densitometric analysis for
the Bad/pBad ratio in LNCaP and PC3 cells respectively. n = 3 independent experiments. *p < 0.05 vs. control. (B) LNCaP (i) and PC3 (iii) cells treated with rfhSP-D
(20µg/ml) for 12 and 24 h were analyzed for anti-Bax (Apoptosis I sampler Kit, Cell Signaling Technology) and anti-Bcl-2 (Apoptosis I sampler Kit, Cell Signaling
Technology) expression by immunoblotting. Panels (ii) and (iv) show densitometric analysis for the Bax/Bcl2 ratio in LNCaP and PC3 cells, respectively. n = 3
independent experiments. *p < 0.05 vs. control, **p < 0.01 vs. control. (C) Immunoblotting for uncleaved anti-Caspase 7(Cell Signaling Technology) and its cleaved
products of molecular mass 32 kDa (upper panel; black arrow) and 20 kDa (lower panel; black arrow) respectively, in rfhSP-D (20µg/ml) treated LNCaP (i) and PC3 (iii)
cells for 24 h. Panels (ii) and (iv) show densitometric analysis for the cleaved caspase 7 and uncleaved caspase 7 in rfhSP-D treated LNCaP and PC3 cells,
respectively. n = 3 independent experiments. *p < 0.05 vs. control. Full length western blots provided as Supplementary Information. (D) Measurement of
Cytochrome c (Human Cyt-C, catalog no. E1516Hu, BT Assay) in cell culture supernatants of normal prostate epithelial cells (PrEC), cancer cell lines (LNCaP and
PC3) and tumor tissue biopsies on exposure to rfhSP-D treatment for 48 h by ELISA. Data are presented as the mean ± S.D from three independent experiments. *p
< 0.05 vs. control. (E) Proposed mechanisms for rfhSP-D mediated apoptosis in PCa cells. Treatment with rfhSP-D upregulates p53 and downregulates pAkt,
resulting in upregulation of Bad, Bax, and release of cytochrome c leading to cleavage of caspase 7 in prostate cancer cells. SP-D interaction with some key
molecules like HMGA1, CD14, SIRPα, and EGFR has been reported previously and may be relevant as part of the proposed mechanisms of p53 and Akt.
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FIGURE 8 | rfhSP-D treatment induced alterations in the transcripts of anti and pro-apoptotic genes. (A,B) Real time RT-PCR analysis showed an upregulation of
transcripts of BAX (ii, v) BAD (iii, vi) and downregulation of BCL2 (i, iv) in LNCaP and PC3 cells on treatment with rfhSP-D (20µg/ml) for 6, 12, and 24 h. Each bar
represents the mean ± S.D of three independent experiments. * indicates statistical significance and *p < 0.05 relative to rfhSP-D untreated controls.
Human prostate cancer tissues frequently exhibit inactivation
of the tumor suppressor gene p53 which is associated with
therapeutic resistance (23). The p53 pathway plays a crucial
role in the transmission of pro-apoptotic signals (24). Various
therapeutic agents/candidates induce apoptosis of LNCaP
(p53+/+) cells by increasing the levels of phosphorylated
p53 (25–27). Knockdown of p53 resulted in blockade of
docetaxel induced apoptotic cell death in prostate cancer
cells (28). Upregulation of activated p53 levels in a time-
dependent manner by rfhSP-D treatment suggested involvement
of the p53 pathway in the induction of apoptosis of LNCaP
cells. Previously, activation of p53 was also observed in
the eosinophilic leukemic cells (AML14.3D10) undergoing
apoptosis upon treatment with rfhSP-D (14, 29). rfhSP-D
treated AML14.3D10 cells showed significantly reduced levels
of HMGA1, a survival protein (14). PC3 cells, a p53 null
and highly metastatic prostate cancer cell line, also showed
significant apoptosis following treatment with rfhSP-D, which
suggested involvement of a p53 independent mechanism of
apoptosis. Among 25% prostate cancer cases, diallelic deletion
of the Phosphatase and tensin homolog (PTEN) gene and
the associated increase in Akt phosphorylation correlates with
hormone refractory prostate cancer (30). Decreased levels of
activated Akt may lead to decreased levels of phosphorylated
Bad (Bcl-2 associated death promoter). Dephosphorylated Bad
interferes with interaction of activated Bcl2 with Bax. Thus,
increased release of Bax triggers apoptosis (31, 32). Decreased
ratio of transcripts of Bcl-2 to Bax has been associated with
cell death following an apoptotic stimulus (33, 34). Both
LNCaP and PC3 cells, upon treatment with rfhSP-D, showed
a significant increase in Bax to Bcl-2 ratio (p < 0.05),
suggesting that besides activation of p53 pathway, rfhSP-D
also inhibited Akt-PI3K pathway leading to induction of Bax
mediated apoptosis. The present study unravels PI3K/Akt, an
anti-apoptotic pathway, as a novel target of rfhSP-D mediated
anti-prostate cancer activity.
Mitochondria plays a central role in the initiation of intrinsic
apoptosis pathway (35). rfhSP-D treatment mediated disruption
of the mitochondria was elucidated by its reduced ability to
oxidize methyl tetrazolium to form formazan crystals (MTT
assay; Figure 4). Breakdown of mitochondria is followed by
the release of cytochrome c (Figure 7), a key initial step in
the irreversible apoptotic process (35, 36). Culture supernatants
from the rfhSP-D treated prostate cancer cells and cancer tissue
biopsies showed significantly elevated levels of cytochrome c,
confirming induction of intrinsic apoptosis. Once in the cytosol,
the cytochrome c interacts with its adaptor molecule, Apaf-
1, resulting in the processing and activation of pro-caspase-9
(37). Caspase-9, in turn, cleaves and activates pro-caspases−3
and−7, effector caspases responsible for the cleavage of various
proteins leading to the biochemical and morphological features
observed in apoptosis (38). Treatment of the prostate cancer
cells with rfhSP-D resulted in the cleavage and activation of
the effector caspase-7, thus leading to programmed cell death.
Nuclear condensation, membrane and nuclear blebbing and
flipping of phosphatidylserine (PS) on the cell membranes, the
typical morphological characteristics of apoptotic cells, were
observed in the rfhSP-D treated prostate cancer cells, confirming
apoptotic cell death. The proposed mechanisms for the rfhSP-
D mediated apoptosis in prostate cancer cells as revealed in
this study along with some key molecules of these pathways
interacting with/ induced by SP-D as reported previously have
been depicted in Figure 7E.
Recent studies highlighted the suppressive role of SP-D
in extrinsic apoptosis wherein native purified human SP-D
interacted with Jurkat T cells and delayed the progression of
Fas (CD95)-Fas ligand and TRAIL-TRAIL receptor induced, but
not TNF-TNF receptor-mediated apoptosis (39). In a subsequent
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study from the same group in UV irradiated Jurkat T cells,
SP-D reduced the activation of caspase-8, executioner caspase-
3 and exposure of phosphatidylserine (PS) on the membranes
of dying cells, with a concomitant increase in the formation of
nuclear and membrane blebs (16). The involvement of rfhSP-D
in extrinsic apoptotic pathway in prostate cancer cells needs to be
explored further.
rfhSP-D induced a cell cycle arrest in G2/M and G0/G1 phases
of LNCaP and PC3 cells, respectively. We had previously shown
that the rfhSP-D induced elevated p21 expression and inhibited
Cdc2 phosphorylation resulting in reduced activity of Cdc2-
cyclin B1 thus, leading to G2/M arrest in the AML14.3D10 cells
(14). Several genes are common to the pathways involved in
cell cycle regulation and apoptosis (40). The p53 protein plays
a critical role both in the G1/S and G2/M checkpoint while
Retinoblastoma (Rb) protein is a potent inhibitor of the G1 to
S phase transition in the cell cycle (41, 42). Following rfhSP-D
treatment, PC3 cells, which are null p53 but express the wild
type Rb gene, showed an arrest in the G1-phase with significant
reduction in the S-phase cell population. This alluded to the
involvement of a p53 independent mechanism in the rfhSP-D
induced apoptosis in PC3 cells.
Increased interaction of rfhSP-D with the prostate cancer cells
as compared to PrEC, could be due to differential expression of
the receptors. Similar to our previous study with eosinophilic
leukemic cells, rfhSP-D showed interaction with the prostate
cancer cells via carbohydrate recognition domain (CRD) (14).
CRD domain of SP-D is known to interact with CD14, TLR-
2, TLR-4, EGFR, and SIRPα that are reported to be present on
prostate cancer cells and normal prostate tissues (15, 43, 44).
Binding of SP-D with pattern recognition receptors CD14, TLR-
2, and TLR-4 may lead to blockade of their downstream pro-
inflammatory and pro-survival signaling (Figure 7E). Interaction
with SIRPα, involved in the negative regulation of receptor
tyrosine kinase-coupled signaling processes, may result in
recruitment of PI3K, leading to a reduction in the activity of
the downstream kinase Akt (45) (Figure 7E). A recent study
showed that SP-D reduced EGF -EGFR binding through the
interaction between CRD of SP-D and N-glycans of EGFR, thus,
leading to downregulation of EGF signaling in the A549 human
lung adenocarcinoma cells (15) (Figure 7E). Further studies are
needed to elucidate the involvement of CRD and its interacting
partners in downstream signaling of rfhSP-D in the prostate
cancer cells.
Oncogenic mutations disturb the normal cellular functions,
thus, allowing the tumor cells to undergo dysregulated
proliferation, resist pro-apoptotic insults, invade normal tissues,
and most importantly, escape apoptosis. Therefore, induction of
apoptosis in the malignant tumors has evolved as a successful
adjunct anti-cancer strategy. We report that rfhSP-D selectively
triggered intrinsic apoptosis in androgen-dependent as well as
androgen-independent prostate cancer cells, without affecting
normal epithelial cells (PrEC). rfhSP-D also induced apoptotic
cell death in the tissue biopsies from metastatic prostate cancer
patients. Thus, SP-D is likely to act as an integral component
of the human innate immune surveillance against cancer cells.
A great advantage associated with the anti-cancer activity of
rfhSP-D is induction of apoptosis by simultaneous targeting
of multiple cellular signaling pathways including transcription
factors, tumor cell survival factors, protein kinases resulting
in the efficient and selective killing of prostate cancer cells.
Murine models of prostate cancer including the patient-derived
xenograft (PDX) mouse models that mimic human disease
and 3D cell cultures derived from PDX are going to be
valuable tools for the evaluation of therapeutic strategies using
rfhSP-D (46).
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